Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...

Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reduction ...

To improve access to care, many professional organizations have advocated for classifying obesity as a disease. However, the ...

More than 100 million Americans who qualify as overweight could see themselves tip into the obese category under newly ...

Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...

Austin Public Health looks at 10 years worth of mortality data by disease, gender and race in new chronic disease report.

Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for market share, data f ...

Wave Life Sciences could offer significant upside if obesity candidate WVE-007 delivers strong human data. Check out the ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.